Sapience Therapeutics Inc.
Sapience Therapeutics is a clinical-stage biotechnology company dedicated to eliminating hard-to-treat cancers through innovative peptide therapeutics, including SPEARs™ and SPARCs™. They focus on redefining druggability by targeting traditionally elusive oncogenic proteins, delivering precision therapy in oncology, and advancing cutting-edge platforms like ADAPT™ and PADS™. Their mission is to transform outcomes for patients with cancer by targeting what others have deemed unachievable.
Industries
Nr. of Employees
small (1-50)
Sapience Therapeutics Inc.
Products
Lucicebtide (ST101)
An investigational therapeutic peptide developed to antagonize an intracellular oncogenic transcription factor; advanced in clinical development (Phase 2) for glioblastoma and other oncology indications with associated biomarker studies and regulatory interactions.
ST316
An investigational peptide antagonist of β‑catenin / Wnt signaling developed as a first-in-class approach to attenuate Wnt-dependent oncogenic activity; progressed through preclinical studies and into Phase 1/2 clinical evaluation.
FraAP Program
A discovery/development program in the company pipeline (listed as a distinct program in pipeline navigation).
Lucicebtide (ST101)
An investigational therapeutic peptide developed to antagonize an intracellular oncogenic transcription factor; advanced in clinical development (Phase 2) for glioblastoma and other oncology indications with associated biomarker studies and regulatory interactions.
ST316
An investigational peptide antagonist of β‑catenin / Wnt signaling developed as a first-in-class approach to attenuate Wnt-dependent oncogenic activity; progressed through preclinical studies and into Phase 1/2 clinical evaluation.
FraAP Program
A discovery/development program in the company pipeline (listed as a distinct program in pipeline navigation).
Expertise Areas
- Peptide therapeutics
- Protein-protein interaction drug discovery
- Oncology clinical development (Phase I/II)
- Biomarker discovery and translational research
Key Technologies
- Peptide library screening
- Peptide stabilization and optimization
- Intracellular targeting of protein-protein interactions
- β-catenin / Wnt pathway modulation